A
Arti B. Gaur
Researcher at Dartmouth College
Publications - 19
Citations - 3400
Arti B. Gaur is an academic researcher from Dartmouth College. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 8, co-authored 17 publications receiving 3106 citations. Previous affiliations of Arti B. Gaur include Dartmouth–Hitchcock Medical Center.
Papers
More filters
Journal ArticleDOI
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
TL;DR: In this article, the miR-200 miRNA family was found to directly target the mRNA of the E-cadherin transcriptional repressors ZEB1 (TCF8/δEF1) and ZEB2 (SMAD-interacting protein 1 [SIP1]/ZFXH1B).
Journal ArticleDOI
Characterization of MicroRNA Expression Levels and Their Biological Correlates in Human Cancer Cell Lines
Arti B. Gaur,David Jewell,Yu Liang,Dana Ridzon,Jason H. Moore,Caifu Chen,Victor R. Ambros,Mark A. Israel +7 more
TL;DR: Evidence that microRNA expression patterns may mark specific biological characteristics of tumors and/or mediate biological activities important for the pathobiology of malignant tumors is provided.
Journal ArticleDOI
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
TL;DR: Critical in vivo findings demonstrate an important functional linkage between mir-21 and Pdcd4 and further elucidate the molecular mechanisms by which the known high level of mir- 21 expression in glioblastoma can attribute to tumorigenesis--namely, inhibition of PdCD4 and its tumor-suppressive functions.
Journal Article
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors
TL;DR: The data identify miR-200 as a powerful marker and determining factor of the epithelial phenotype of cancer cells as well as an extraordinary marker for cells that express E-cadherin but lack expression of Vimentin.
Journal ArticleDOI
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.
William W. Feng,William W. Feng,Owen M. Wilkins,Scott Bang,Matthew Ung,Jiaqi Li,Jennifer An,Carmen del Genio,Kaleigh Canfield,James DiRenzo,Wendy A. Wells,Arti B. Gaur,Brooks R.B. Robey,Brooks R.B. Robey,Jessie Yanxiang Guo,Ryan L Powles,Christos Sotiriou,Lajos Pusztai,Maria Febbraio,Chao Cheng,William B. Kinlaw,Manabu Kurokawa,Manabu Kurokawa +22 more
TL;DR: During acquisition of resistance to HER2 inhibition, metabolic rewiring of breast cancer cells favors reliance on exogenous FA uptake over de novo FA synthesis, defined as an essential survival mechanism in HER2-positive breast cancer.